ClinicalTrials.gg
CompletedNCT07475663Updated Mar 16, 2026

Counterpain PXM Versus Diclofenac Versus Piroxicam

A Phase 3 interventional study of Piroxicam plus Counterirritant (brand name Counterpain® PXM). and Diclofenac Sodium 10 mg (Brand Name Hotin® DCL) in Ankle Sprain, Back Pain and Osteoarthritis (OA) of the Knee, sponsored by Taisho Pharmaceutical Indonesia. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Taisho Pharmaceutical Indonesia (part of Taisho Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Nov 2025, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if a gel containing Piroxicam plus Counterirritant (warming/cooling ingredients) is as effective and safe as two other common anti-inflammatory gels for treating acute muscle, bone, and joint pain in adults aged 18-60. The main questions it aims to answer are:

Does the Piroxicam plus Counterirritant gel provide a similar level of pain relief as the standard Piroxicam-only gel and the Diclofenac gel?

Is the Piroxicam plus Counterirritant gel as safe to use as the other two gels?

Researchers will compare three groups of participants, each using one of the gels (Piroxicam plus Counterirritant, Piroxicam-only, or Diclofenac) to see if the combination gel works equally well.

Participants will:

  • Be randomly assigned to use one of the three gels for approximately 6 days.
  • Visit the clinic three times (at the start, midpoint, and end) for pain assessments, physical exams (checking movement and muscle strength), and physiotherapy sessions.
  • Apply their assigned gel at home three times daily (morning, afternoon, evening) and record their gel use and pain levels in a provided diary.
  • Receive a rescue medication (paracetamol) to use only if their pain becomes unbearable and record when they take it.
Read the detailed description

The primary goal is to demonstrate that a gel containing the active ingredients Piroxicam plus Counterirritant is equally effective and safe as two other widely used gels in reducing pain. The three gels being compared are:

  1. Test Gel: Piroxicam plus Counterirritant (brand name Counterpain® PXM). This gel combines an anti-inflammatory drug (Piroxicam) with ingredients that create a distinct warming or cooling sensation on the skin (methyl salicylate, eugenol, and menthol).
  2. Comparator Gel A: Piroxicam gel only (brand name Pirofel®). This gel contains the anti-inflammatory drug Piroxicam by itself.
  3. Comparator Gel B: Diclofenac gel (brand name Hotin® DCL). This is another very common and well-studied anti-inflammatory gel, often considered a standard treatment for this type of pain.

    The study's central hypothesis is that the Piroxicam-plus-counterirritant gel is not inferior to the other two and provides a similar level of pain relief and safety. This type of study is called an equivalence trial.

    How is the Study Designed?

    This is a Phase 3, Randomized, Controlled, Multi-center, Single-blind, Parallel-group study. Here's what each of these terms means:

    • Phase 3: This is a confirmatory stage of research, often done after a product is already on the market, to confirm its effectiveness and safety in a larger group of people compared to standard treatments.
    • Randomized: Participants will be assigned to one of the three gel groups purely by chance, using a computer-generated list (like flipping a coin). This randomization is the best way to ensure the three groups are comparable at the start of the study, minimizing bias in the final results.
    • Controlled: The test gel (Piroxicam plus Counterirritant) is being compared against two "control" groups who are using other known and accepted treatments (Piroxicam-only and Diclofenac gels).
    • Multi-center: The study will take place at two different clinic locations: Klinik Utama Eminence and St. Carolus Sports Clinic by Eminence. This helps in recruiting enough participants and makes the results more generalizable to the wider population.
    • Single-blind: In this type of study, the participants do not know which gel they are using. To achieve this, all the original gel tubes will be completely covered with a plain white sticker, hiding their brand identity. They will only have a study label with a unique code. This prevents the participants' expectations (e.g., thinking a particular brand works better) from influencing how they report their pain. The doctors and physiotherapists who assess the participants will also not know which gel corresponds to which code, ensuring their evaluations are objective. Only the study coordinator and the principal investigator will have access to the master list that links the codes to the actual gels.
    • Parallel-group: This means that each participant will only use one type of gel for the entire duration of the study. They will not switch to another gel.

    How Long Will the Study Last for Each Person?

    The total duration of participation for each individual is 6 ± 1 days. This means the study period could be anywhere from 5 to 7 days. During this time, participants will need to visit the clinic three times:

    • Visit 1 (Day 0): The initial screening, enrollment, and first treatment visit.
    • Visit 2 (Day 3 ± 1 day): A follow-up visit about halfway through the study.
    • Visit 3 (Day 6 ± 1 day): The final visit to conclude the study.

    Who Can Take Part in the Study? (Inclusion and Exclusion Criteria) To ensure the study is fair, safe, and that the results are clear and reliable, only people who meet very specific requirements can participate.

    Inclusion Criteria (who can join):

    - Outpatients at one of the two study clinics.

    • Adults aged 18 to 60 years old.
    • Diagnosed with acute (sudden-onset) musculoskeletal pain. This specifically includes:
    • Osteoarthritis of a joint, with a severity of Grade 0 to III on the Kellgren-Lawrence scale (a standard way to grade osteoarthritis from X-rays). This means mild to moderate arthritis.
    • Specific musculoskeletal disorders such as: Ankle sprain, Patellar tendinitis, Tennis elbow (lateral epicondylitis) \& Back pain
    • Able to read and understand how to fill out the pain assessment forms and the participant diary.
    • Willingly provide written consent to participate in the study by signing the informed consent form.

    Exclusion Criteria (who cannot join):

    • People with severe osteoarthritis (Grade IV on the Kellgren-Lawrence scale).
    • Those who have recently had certain medical procedures on the affected joint (e.g., draining fluid, joint injections).
    • Individuals currently taking strong painkillers (opioid analgesics) or blood thinners (like warfarin, clopidogrel).
    • Those who have taken oral corticosteroids in the 3 days before the study starts.
    • People with certain medical conditions, including: Neuropsychiatric disorders (depression, dementia, etc.), Severe, uncontrolled hypertension (high blood pressure), Acute peptic ulcers, Bronchial asthma or a history of aspirin-induced asthma, A known allergy or hypersensitivity to NSAIDs (like piroxicam, diclofenac, or aspirin), Serious liver, kidney, heart, blood disorders, or cancer, Skin conditions (dermatitis) or wounds at the area where the gel would be applied.
    • Women who are pregnant, planning to become pregnant, or are currently breastfeeding.
    • Anyone considered by the investigator to be unsuitable for the study for any other reason.

    What Will Happen During the Study Visits? The process is carefully structured for each of the three visits. This ensures consistency and that all necessary data is collected correctly.

    Visit 1 (Day 0 - The Start):

    Registration \& Screening: A person with pain registers at the clinic. The research team explains the study in detail. If interested, the participant reads and signs the Informed Consent Form, a document confirming they understand the study and voluntarily agree to take part.

    Initial Assessments:

    • The participant fills out a questionnaire about their pain (the "Brief Pain Inventory" - Form 2).
    • A doctor (Principal Investigator or Sub-Investigator) performs a medical interview and physical exam. This includes checking the location and nature of the pain, measuring the Range of Motion (ROM) of the affected joint and testing muscle strength (Form 6). If clinically needed, an X-ray may be taken.
    • Randomization \& First Treatment: The study coordinator uses a computer to randomly assign the participant to one of the three gel groups.
    • The participant receives their first application of the gel from a physiotherapist in the therapy room. The physiotherapist records this (Form 7).
    • Immediately after the gel is applied, the participant fills out a short form about the thermal sensation they feel (e.g., cool, warm, neutral, hot) and how long it took to feel that sensation (Form 8).
    • Physiotherapy: The participant receives a standardized physiotherapy session based on their specific diagnosis. For example, a person with an ankle sprain will do different exercises than someone with back pain. This session is documented by the physiotherapist (Form 9).

    Take-Home Kit: The participant is given a pouch containing everything they need for the next few days:

    - 2 tubes of their assigned study gel.

    - 3 dosing cards (to help measure the correct amount of gel each time).

    - 4 strips of rescue medication (paracetamol 600mg tablets).

    - A participant diary to record gel applications, pain levels, and any other medications taken. Business cards for the study coordinator and doctor.

    At Home (Between Visits):

    - The participant applies the gel at home three times a day (morning, afternoon, evening) using the dosing card.

    - They record each application and any changes in their pain in the diary.

    - The study coordinator will send daily reminders (e.g., by phone or text) to help with compliance.

    - If the pain becomes unbearable, the participant can take the paracetamol (rescue medication) and must record the date and time in the diary.

    Visit 2 (Day 3 ± 1 day - The Midpoint):

    - The participant returns to the clinic, bringing back their pouch with all remaining products and their completed diary.

    - They re-register and meet with the doctor. The same assessments from Visit 1 are repeated (pain questionnaires, ROM, muscle strength).

    • They receive another physiotherapy session and another application of their assigned gel from the physiotherapist. They again fill out the thermal sensation form.
    • They are given a new pouch with a fresh supply of study gel, dosing cards, and rescue medication to continue the treatment at home until the final visit.

    Visit 3 (Day 6 ± 1 day - The End):

    • The process is the same as Visit 2.
    • The participant returns all remaining products and the completed diary for the final time.
    • After the final assessments and physiotherapy session, the doctor informs them that the study is complete.
02

Conditions studied

  • Ankle Sprain
  • Back Pain
  • Osteoarthritis (OA) of the Knee
  • Tennis Elbow
  • Runner's Knee
03

In context

Ankle Injuries

353 studies on the registry are indexed under Ankle Injuries; 74 are open to participants now.

This study's enrollment of 180 is above the median of 54 across 271 interventional studies indexed under Ankle Injuries.

Browse Ankle Injuries studies →

Lead sponsor

Taisho Pharmaceutical Indonesia is the lead sponsor of 2 studies on the registry; none are open to participants now.

First submitted after Taisho Pharmaceutical Indonesia became part of Taisho Pharmaceutical Co., Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatient in a health care setting.
  • Between the ages of 18 - 60 years of either sex.
  • Patients diagnosed with musculoskeletal pain as described in the target population.
  • Patient can read and understand how to fill out the assessment form and diary.
  • Patients gave written consent to participate in the study independently.

Exclusion criteria

Exclusion Criteria:

  • Patient who has osteoarthritis with Grade IV Kellgren-Lawrence (KL) grading. - - Patients who underwent any of the following treatments:
  • Paracentesis and drainage of joint
  • Intraarticular injection (joint protection agents, local anesthetic, etc.)
  • Nerve block (including trigger points)
  • Patients are being treated with an analgesic opioids for their musculosceletal pain.
  • Patients being treated with anti coagulant therapy such as warfarin, clopidogrel.
  • Patients being treated with oral 3 days before and until signed the .
  • Patients being treated using rigid orthoses those requiring such treatment
  • Patients with neuropsychiatric disorders including depression, dementia, schizophrenia, and anxiety neurosis
  • Patients with Grade 3 hypertension (systolic blood pressure ≥ 180 mmHg and diastolic blood pressure ≥ 110 mmHg regardless of the use of an antihypertensive drugs)
  • Patients with acute peptic ulcer
  • Patients with bronchial asthma with current or previous aspirin-induced asthma (asthmatic attacks induced by NSAIDs and other relevant drugs)
  • Patients with a history of or allergy to NSAIDs
  • Patients with serious hepatic disease, renal disease, cardiac disease, hematologic disease, or
  • Patients with a history of dermatitis requiring treatment with topical agents
  • Patients with dermatitis or wounds at the application site of the study drug
  • Pregnant women ,women who may be pregnant, women who wish to become pregnant during the study, or nursing women
  • Patients considered by the Investigator to be inappropriate as participants of this study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    PXM + Counterirritant

    Apply gel to the affected area three times daily leaving no residual material on the skin.1 gram of gel ( \~ 3 cm) applied to the affected area.

    Drug: Piroxicam plus Counterirritant (brand name Counterpain® PXM).

  • Active comparator
    Comparator Drugs

    Apply gel to the affected area three times daily leaving no residualmaterial on the skin. 1 gram of gel ( \~ 3 cm) applied to the affected area.

    Drug: Diclofenac Sodium 10 mg (Brand Name Hotin® DCL) · Drug: Piroxicam 0.5% (Brand name Pirofel® gel)

Interventions

  • DrugPiroxicam plus Counterirritant (brand name Counterpain® PXM).

    Participants assigned to this intervention group will use Piroxicam plus Counterirritant gel (Counterpain® PXM) . Each application involves dispensing approximately 1 gram (3 cm) of gel onto a provided dosing card and applying it directly to the painful area. The gel contains 0.5% Piroxicam as the anti-inflammatory agent, combined with three counterirritants: Methyl Salicylate, Menthol, and Eugenol. These counterirritants produce distinct warming and cooling sensations upon application. Participants will apply the gel three times daily (morning, afternoon, evening) for 6 ± 1 days. The total number of applications and the timing of the perceived thermal sensation will be recorded in a participant diary. This intervention is distinct from the comparator arms (Piroxicam-only and Diclofenac gels) specifically due to the presence of these counterirritant ingredients, which are intended to provide additional symptomatic relief through sensory stimulation.

  • Dose : Refer to the product's leaflet : no occlusive dress should be employed. Apply the required amount of cream on the affected area three times a day and rub gently. The amount of cream needed depends on the extent of the painful area. The affected area are : * In the arms: hand, wrist, elbow, shoulder sinistra or dextra * In the legs: feet, ankle, knee sinistra or dextra * Upper back or Lower back 3 times daily means : * application one time in morning (06.00 - 11.00), o one time in afternoon (11.01 - 17.00), * one time in evening (17.01 - 23.00). Aplication of gel will use dosing card that provided in this clinical study. * Method of administration: external use only. * Every visit, participants will get 2 tubes and in total are 6 tubes for 6 + 1 days application

  • Dose: Apply gel to the affected area three times daily leaving no residual material on the skin. 1 gram of gel applied to the affected area. The affected area are : * In the arms: hand, wrist, elbow, shoulder sinistra or dextra * In the legs: feet, ankle, knee sinistra or dextra * Upper back or Lower back 3 times daily means : * application one time in morning (06.00 - 11.00) * one time in afternoon (11.01 - 17.00), * one time in evening (17.01 - 23.00). Aplication of gel will use dosing card that provided in this clinical study. * Method of administration: external use only. * Every visit, participants will get 2 tubes and in total are 6 tubes for 6 + 1 days application.

06

What researchers measure

Primary outcomes

  1. The primary end-point is the difference of musculoskeletal pain reduction > 3 scores , of the response to treatment that can be seen through Brief Pain Inventory (BPI) scores.

    The Brief Pain Inventory (BPI) scores is a medical questionnaire that is used to assess pain. It has also been validated for pain assessment chronicle. There are 9 questions related to the pain experienced by the participants. The pain assessment will be given in the form of a score, namely a score of 0 - 10. The difference BPI scale \> 3 , from initial scale of pain to the end of treatment will be captured as the primary efficacy endpoint. The selection of difference more than equal to 3 was chosen because if the participant has moderate pain at the beginning of the treatment, then at the end of the treatment there is a decrease in pain to mild pain. This can be seen that the treatment is effective in dealing with musculoskeletal pain

    Time frame: From enrollment to the end of treatment at 4 months

07

Study locations

1 site
  • St. Carolus Sports Clinic & Klinik Utama Eminence
    Jakarta, DKI Jakarta 10440, Indonesia
08

References and documents

Publications

  • Derry S, Moore RA, Gaskell H, McIntyre M, Wiffen PJ. Topical NSAIDs for acute musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015 Jun 11;2015(6):CD007402. doi: 10.1002/14651858.CD007402.pub3. PubMed 26068955 ↗
  • Kocak AO, Dogruyol S, Akbas I, Menekse TS, Gur STA, Kocak MB, Cekmen B, Orun S, Cakir Z. Comparison of topical capsaicin and topical piroxicam in the treatment of acute trauma-induced pain: A randomized double-blind trial. Am J Emerg Med. 2020 Sep;38(9):1767-1771. doi: 10.1016/j.ajem.2020.05.104. Epub 2020 Jun 2. PubMed 32739846 ↗
  • Stratford PW, Binkley J, Solomon P, Gill C, Finch E. Assessing change over time in patients with low back pain. Phys Ther. 1994 Jun;74(6):528-33. doi: 10.1093/ptj/74.6.528. PubMed 8197239 ↗
  • Cleland JA, Mintken PE, McDevitt A, Bieniek ML, Carpenter KJ, Kulp K, Whitman JM. Manual physical therapy and exercise versus supervised home exercise in the management of patients with inversion ankle sprain: a multicenter randomized clinical trial. J Orthop Sports Phys Ther. 2013;43(7):443-55. doi: 10.2519/jospt.2013.4792. Epub 2013 Apr 29. PubMed 23628755 ↗
  • Mizner RL, Petterson SC, Snyder-Mackler L. Quadriceps strength and the time course of functional recovery after total knee arthroplasty. J Orthop Sports Phys Ther. 2005 Jul;35(7):424-36. doi: 10.2519/jospt.2005.35.7.424. PubMed 16108583 ↗
  • McMahon SB, Dargan P, Lanas A, Wiffen P. The burden of musculoskeletal pain and the role of topical non-steroidal anti-inflammatory drugs (NSAIDs) in its treatment. Ten underpinning statements from a global pain faculty. Curr Med Res Opin. 2021 Feb;37(2):287-292. doi: 10.1080/03007995.2020.1847718. Epub 2020 Nov 20. PubMed 33155849 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2025 to primary completion in Feb 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2026
First posted
Mar 16, 2026
StartActual
Nov 4, 2025
Primary completionActual
Feb 12, 2026
CompletionActual
Feb 12, 2026
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07475663
Responsible party
Erica Kholinne (Principal Investigator, Taisho Pharmaceutical Indonesia) — Principal investigator
First posted
Mar 16, 2026
Start date
Nov 4, 2025
Primary completion
Feb 12, 2026
Completion
Feb 12, 2026
Last update
Mar 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion